Bristol-Myers Squibb

The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
Motley Fool
cancer
cancer immunotherapies
Opdivo
Bristol-Myers Squibb
Keytruda
Merck
Yervoy
Flag link:
Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
Motley Fool
Halozyme
Inovalon
Teva Pharmaceutical
Unitedhealthcare Group
Roche
Bristol-Myers Squibb
Flag link:
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Motley Fool
AbbVie
Humira
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Biogen
aducanumab
Flag link:
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Motley Fool
Exelixis
Bristol-Myers Squibb
kidney cancer
Cabometyx
Opdivo
Yervoy
Flag link:
Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take
Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take
Forbes
Bristol-Myers Squibb
Halozyme
Opdivo
Flag link:
Cancer patients know immuno-oncology and top drugs, but lack details: study
Cancer patients know immuno-oncology and top drugs, but lack details: study
Fierce Pharma
patients
cancer
immuno-oncology
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Flag link:
With Yervoy-beating data, Opdivo poised to fight melanoma's return after surgery
With Yervoy-beating data, Opdivo poised to fight melanoma's return after surgery
Fierce Pharma
Yervoy
Opdivo
Bristol-Myers Squibb
melanoma
Flag link:
Opdivo combo shows early survival benefit in kidney cancer
Opdivo combo shows early survival benefit in kidney cancer
BioPharma Dive
Opdivo
Yervoy
Bristol-Myers Squibb
kidney cancer
Flag link:
FDA orders Bristol-Myers’ Opdivo to the sidelines on 3 studies as regulators explore dangers of checkpoint combos
FDA orders Bristol-Myers’ Opdivo to the sidelines on 3 studies as regulators explore dangers of checkpoint combos
Endpoints
FDA
Bristol-Myers Squibb
Opdivo
clinical trials
Multiple Myeloma
Flag link:
Infographic | The leaders of the global hepatitis-C market
Infographic | The leaders of the global hepatitis-C market
Medical Marketing and Media
hepatitis C
Gilead Sciences
Merck
AbbVie
Bristol-Myers Squibb
Flag link:
Bristol-Myers, Pfizer continue to build case for Eliquis
Bristol-Myers, Pfizer continue to build case for Eliquis
BioPharma Dive
Bristol-Myers Squibb
Pfizer
Eliquis
blood thinners
Flag link:
Pharma Stocks That Could Move On New Data
Pharma Stocks That Could Move On New Data
Barron's
pharma stocks
AbbVie
Bayer
Novartis
Bristol-Myers Squibb
Eli Lilly
European Society of Cardiology
Flag link:
An analysis of 2017 first half for pharmaceutical industry
An analysis of 2017 first half for pharmaceutical industry
GoInPharma
pharma industry
Pfizer
Sanofi
GSK
Roche
Celgene
Bristol-Myers Squibb
Flag link:
Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017
Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017
Market Realist
Opdivo
Bristol-Myers Squibb
Flag link:
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Xconomy
Bristol-Myers Squibb
kidney cancer
Opdivo
Yervoy
Flag link:
A Supreme Court pharma case deals consumers a big loss
A Supreme Court pharma case deals consumers a big loss
Stat
Supreme Court
consumers
Plavix
Bristol-Myers Squibb
Flag link:
Pharma's giants, new and old, tell more tales than their numbers show
Pharma's giants, new and old, tell more tales than their numbers show
Fierce Pharma
Big Pharma
JNJ
Pfizer
GSK
Roche
Novartis
Sanofi
Bristol-Myers Squibb
Flag link:
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
pharma stocks
Merck
Pfizer
AbbVie
Eli Lilly
Bristol-Myers Squibb
GSK
Roche
Sanofi
Bayer
Novo Nordisk
Celgene
Biogen
AstraZeneca
Flag link:
Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff
Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff
Fierce Pharma
Bristol-Myers Squibb
HIV
layoffs
patent cliff
Reyataz
Sustiva
Flag link:
Bristol-Myers beefs up big cancer drug pipeline, buying IFM drugs in $2.3B-plus deal
Bristol-Myers beefs up big cancer drug pipeline, buying IFM drugs in $2.3B-plus deal
Endpoints
Bristol-Myers Squibb
IFM Therapeutics
oncology
M&A
Flag link: